Format

Send to

Choose Destination
Curr Oncol. 2018 Jun;25(Suppl 1):S59-S67. doi: 10.3747/co.25.3760. Epub 2018 Jun 13.

ALK inhibitors, resistance development, clinical trials.

Author information

1
RS McLaughlin Durham Regional Cancer Centre, Oshawa, and Department of Oncology, Queen's University, Kingston, ON.
2
Department of Medical Oncology, BC Cancer, Vancouver, BC.

Abstract

The treatment of advanced non-small-cell lung cancer (nsclc) has undergone a paradigm shift since the early 2000s. The identification of molecular subtypes of the disease, based on oncogenic drivers, has led to the development of personalized medicine and the ability to deliver molecularly targeted therapies to patients. In the 10 years that have elapsed since the discovery of the ALK gene in a patient with nsclc, several active drugs have moved rapidly from bench to bedside, and multiple others are currently in clinical trials. Those developments have led to important improvements in patient outcomes, while simultaneously raising key questions about the optimal treatment for ALK-positive nsclc. The inevitable emergence of resistance to alk-directed therapy is central to ongoing research and daily clinical practice for affected patients. In the present review, we highlight the current treatment landscape, the available and emerging clinical trials, and the evolving clinical decision-making in ALK-positive nsclc, with a focus on Canadian practice.

KEYWORDS:

alectinib; alk inhibitors; brigatinib; ceritinib; cns metastases; crizotinib; nsclc; resistance

Supplemental Content

Full text links

Icon for Multimed Inc. Icon for PubMed Central
Loading ...
Support Center